American International Group, Inc. Share Price Target ‘$85.00’, now 7.8% Upside Potential

DirectorsTalk Interviews

American International Group, Inc. with ticker code (AIG) now have 16 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $92.00 and $75.00 calculating the average target share price we see $85.00. (at the time of writing). Now with the previous closing price of $78.82 this now indicates there is a potential upside of 7.8%. The day 50 moving average is $77.09 while the 200 day moving average is $68.44. The company has a market cap of 51.98B. The stock price is currently at: $78.32 USD

The potential market cap would be $56,053,923,435 based on the market consensus.

The company has a dividend yield of 0.89%. Other points of data to note are a P/E ratio of 11.71, revenue per share of $68.56 and a 0.82% return on assets.

American International Group, Inc. is a global insurance company. The Company provides a range of property and casualty insurance, life insurance, retirement solutions, and other financial services to customers in over 70 countries and jurisdictions. Its diverse offerings include products and services that help businesses and individuals protect their assets, manage risks and provide for retirement security. It operates through three segments: General Insurance, Life and Retirement, and Other Operations. Its General Insurance segment consists of two segments: North America and International. Its Life and Retirement segment consists of four segments: Individual Retirement, Group Retirement, Life Insurance and Institutional Markets. Its North America and International segments consist of two product categories: Commercial Lines, which consists of Liability, Financial Lines, Property and Global Specialty, and Personal Insurance, which consists of Personal Lines, and Accident and Health.

Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search